Contineum Therapeutics, Inc. SEC filings CTNM
Contineum Therapeutics, Inc. has 201 filings in SEC EDGAR's recent list, going back to Dec 13, 2023. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 23, 2025 | — |
| CORRESP | Letter to the SEC | May 21, 2025 | — |
| UPLOAD | Letter from the SEC | May 20, 2025 | — |
| SEC STAFF LETTER | Filing | Apr 5, 2024 | — |
| EFFECT | Filing | Apr 4, 2024 | — |
| CERT | Filing | Apr 4, 2024 | — |
| 8-A12B | Filing | Apr 2, 2024 | — |
| CORRESP | Letter to the SEC | Apr 2, 2024 | — |
| CORRESP | Letter to the SEC | Apr 2, 2024 | — |
| CORRESP | Letter to the SEC | Mar 21, 2024 | — |
| CORRESP | Letter to the SEC | Mar 15, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 23, 2024 | — |
| DRSLTR | Filing | Feb 15, 2024 | — |
| DRS/A | Filing | Feb 15, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 7, 2024 | — |
| DRSLTR | Filing | Jan 29, 2024 | — |
| DRS/A | Filing | Jan 29, 2024 | — |
| SEC STAFF LETTER | Filing | Jan 25, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 11, 2024 | — |
| DRS | Filing | Dec 13, 2023 | — |
Showing 20 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CTNM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1855175
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.